机译:高危低危弥漫性大B细胞淋巴瘤和中度至高度“生命威胁”影响型心脏病的老年患者每两周一次利妥昔单抗,环磷酰胺,长春新碱,非聚乙二醇化脂质体包裹的阿霉素和泼尼松(R-COMP-14)
Haematology-Oncology and Stem Cell Transplantation Unit National Cancer Institute Fondazione ‘G. Pascale’ IRCCS;
Haematology A.O. San Gennaro ASL NA1;
EGBP Surgery Department of Abdominal Surgery D National Cancer Institute Fondazione ‘G. Pascale’ IRCCS;
Cardiology National Cancer Institute Fondazione ‘G. Pascale’ IRCCS;
Department of Cellular and Molecular Biology and Pathology Faculty of Biotechnological Sciences Federico II University Naples Italy;
non-pegylated liposomal doxorubicin; elderly; diffuse large B-cell lymphoma; cardiotoxicity; Charlson Comorbidity Index;
机译:高危低危弥漫性大B细胞淋巴瘤和中度至高危生命威胁心脏病的老年患者每两周一次利妥昔单抗,环磷酰胺,长春新碱,非聚乙二醇化脂质体包裹的阿霉素和泼尼松(R-COMP-14)。
机译:环磷酰胺,阿霉素,长春新碱,泼尼松和利妥昔单抗与表柔比星,环磷酰胺,长春花碱,泼尼松和利妥昔单抗用于老年“适合”弥漫性大B细胞淋巴瘤患者的初始治疗:Intergruppo Italiano Linfomi的ANZINTER3试验结果
机译:Lenalidomide维持与安慰剂相比,在响应弥漫性大型B细胞淋巴瘤的老年患者中,用一线rituximab加环磷酰胺,多柔比星,长春克里酮和泼尼松
机译:高危低危弥漫性大B细胞淋巴瘤和中度至高危生命威胁型心脏病老年患者每两周一次利妥昔单抗环磷酰胺长春新碱非聚乙二醇化脂质体包裹的阿霉素和泼尼松(R-COMP-14)
机译:高危低危弥漫性大B细胞淋巴瘤和中度至高度“生命威胁”影响型心脏病的老年患者每两周一次利妥昔单抗,环磷酰胺,长春新碱,非聚乙二醇化脂质体包裹的阿霉素和泼尼松(R-COMP-14)